Experimental drug tested for aggressive blood cancer
NCT ID NCT04674813
Summary
This early-stage study tested an experimental drug called CC-95266 in 130 adults with multiple myeloma that had returned or stopped responding to previous treatments. The main goal was to find the safest dose and check for side effects, while also looking for early signs that the drug might help control the cancer. Participants had already tried several other treatments without success.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution - 001
Nashville, Tennessee, 37203, United States
-
Local Institution - 002
Denver, Colorado, 80218, United States
-
Local Institution - 003
Seattle, Washington, 98104, United States
-
Local Institution - 005
Birmingham, Alabama, 10016, United States
-
Local Institution - 006
Dallas, Texas, 75390, United States
-
Local Institution - 008
Baltimore, Maryland, 21201, United States
-
Local Institution - 009
Duarte, California, 91010-301, United States
-
Local Institution - 010
Boston, Massachusetts, 02215, United States
-
Local Institution - 011
New York, New York, 10029, United States
-
Local Institution - 012
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.